Table 4.
Clinical and demographic data of patients with replicant and persistent HAdV detected in palatine tonsils
| Disease patients group | Control patients group | |||
|---|---|---|---|---|
| Replicant HAdV | Persistent HAdV | Replicant HAdV | Persistent HAdV | |
| Patients | 4 (8.2%) | 45 (91.8%) | 0 (0.0%) | 2 (100.0%) |
| Males | 2 (50.0%) | 21 (42.3%) | – | 1 (50.0%) |
| Age (median of years) | 4.0 | 5.0 | – | 3.0 |
| Viral coinfection | 3 (75.0%) | 30 (66.6%) | – | 0 (0.0%) |
| Viral load (median copies/g) | 9.56 × 105 | 4.50 × 104 | – | 1.8 × 104 |
| High viral load (>106)* | 2 (50.0%) | 5 (11.1%) | – | 0 (0.0%) |
| Detection in several sites | 4 (100.0%) | 37 (82.2%) | – | 2 (100%) |
| Spreading of HAdV in NPS | 3 (75.0%) | 20 (44.4%) | ||
| Recurrent tonsillitis | 3 (75.0%) | 26 (57.7%) | – | – |
| Tonsillar hypertrophy | 4 (100.0%) | 37 (82.2%) | – | – |
| Sleep apnea | 4 (100.0%) | 25 (55.5%) | – | – |
| Otitis media with effusion | 0 (0.0%) | 8 (17.7%) | – | – |
| Allergy | 1 (25.0%) | 13 (28.8%) | – | – |
Abbreviations: HAdV, human adenovirus; NPS, nasopharyngeal secretion.
*
P < 0.05.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.